Food and Drug Administration Electronic Submissions Gateway, 45057-45058 [E6-12808]
Download as PDF
Federal Register / Vol. 71, No. 152 / Tuesday, August 8, 2006 / Notices
and falsifying patient data in research
supported by National Institute on
Aging (NIA), National Institutes of
Health (NIH), grant R01 AG18461.
Specifically, Ms. Okoro intentionally
and knowingly fabricated and falsified
data for six visit dates on one patient
data form and falsified and fabricated
patient condition information on two
additional study subjects by failing to
note that each patient had experienced
a fall as documented in their medical
charts.
ORI has implemented the following
administrative actions for a period of
three (3) years, beginning July 17, 2006:
(1) Ms. Okoro is prohibited from
serving in any advisory capacity to PHS,
including but not limited to service on
any PHS advisory committee, board,
and/or peer review committee, or as a
consultant; and
(2) Any institution that submits an
application for PHS support for a
research project on which Ms. Okoro’s
participation is proposed or which uses
her services in any capacity on PHS
supported research must concurrently
submit a plan for supervision of her
duties. The supervisory plan must be
designed to ensure the scientific
integrity of Ms. Okoro’s research
contribution and must be submitted to
ORI by the institution.
FOR FURTHER INFORMATION CONTACT:
Director, Division of Investigative
Oversight, Office of Research Integrity,
1101 Wootton Parkway, Suite 750,
Rockville, MD 20852, (240) 453–8800.
Chris B. Pascal, J.D.,
Director, Office of Research Integrity.
[FR Doc. E6–12857 Filed 8–7–06; 8:45 am]
BILLING CODE 4150–31–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
Science Advisory Board to the
National Center for Toxicological
Research; Notice of Meeting
AGENCY:
Food and Drug Administration,
HHS.
jlentini on PROD1PC65 with NOTICES
ACTION:
Notice.
This notice announces a forthcoming
meeting of a public advisory committee
of the Food and Drug Administration
(FDA). At least one portion of the
meeting will be closed to the public.
Name of Committee: Science
Advisory Board (SAB) to the National
Center for Toxicological Research
(NCTR).
General Function of the Committee:
The Board advises the Director, NCTR,
VerDate Aug<31>2005
20:06 Aug 07, 2006
Jkt 208001
in establishing, implementing, and
evaluating the research programs that
assist the Commissioner of Food and
Drugs in fulfilling his regulatory
responsibilities. The Board provides an
extra-agency review in ensuring that the
research programs at NCTR are
scientifically sound and pertinent.
Date and Time: The meeting will be
held on August 29, 2006 from 8:30 a.m.
to 4:30 p.m. and on August 30, 2006,
from 8 a.m. to 12 noon.
Location: August 29, 2006: NCTR SAB
Conference Room B–12, 3900 NCTR Dr.,
Jefferson, AR 72079. August 30, 2006:
University of Arkansas for Medical
Sciences, Stephens Spine Center,
Hamlin Board Room, 501 Jack Stephens
Dr., Little Rock, AR 72205.
Contact Person: Leonard Schechtman,
Executive Secretary, National Center for
Toxicological Research, Food and Drug
Administration, 5600 Fishers Lane, rm.
16–85, Rockville, MD 20857, 301–827–
6696, or FDA Advisory Committee
Information Line, 1–800–741–8138
(301–443–0572 in the Washington, DC
area), code 3014512559. Please call the
Information Line for up-to-date
information on this meeting.
Agenda: On August 29, 2006, the SAB
will hear presentations from the NCTR
Divisions that will update them on
ongoing research activities. The SAB
will be presented with a response to the
evaluation of the Division of
Neurotoxicology. The evaluation was
the product of a site visit team that
conducted an on-site review of the
Division in January 2004. The response
will address the issues raised and
recommendations made by the site visit
team. On August 30, 2006, the NCTR
Director will provide a Center-wide
update on scientific endeavors and will
discuss the NCTR realignment and
strategic focus.
Procedure: On August 29, 2006, from
8:30 a.m. to 4:30 p.m., and August 30,
2006, from 8 a.m. to 10:30 a.m., the
meeting is open to the public. Interested
persons may present data, information,
or views, orally or in writing, on issues
pending before the committee. Written
submissions may be made to the contact
person on or before August 14, 2006.
Oral presentations from the public will
be scheduled on August 29, 2006,
between approximately 12:30 p.m. to
1:30 p.m. Time allotted for each
presentation may be limited. Those
desiring to make formal oral
presentations should likewise notify the
contact person and submit a brief
statement of the general nature of the
evidence or arguments they wish to
present, the names and addresses of
proposed participants, and an
indication of the approximate time
PO 00000
Frm 00064
Fmt 4703
Sfmt 4703
45057
requested to make their presentation on
or before August 14, 2006.
Closed Committee Deliberations: On
August 29, 2006, from approximately 11
a.m. to 12:30 p.m., the meeting will be
closed to permit discussion where
disclosure would constitute a clearly
unwarranted invasion of personal
privacy (5 U.S.C. 552b(c)(6)). This
portion of the meeting will be closed to
permit discussion of information
concerning individuals associated with
the research programs at NCTR.
Persons attending FDA’s advisory
committee meetings are advised that the
agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with physical
disabilities or special needs. If you
require special accommodations due to
a disability, please contact the office of
the Executive Secretary at least 7 days
in advance of the meeting.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: August 2, 2006.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. E6–12863 Filed 8–7–06; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. 1992S–0251] (formerly 92S–
0251)
Food and Drug Administration
Electronic Submissions Gateway
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing the
availability of the FDA Electronic
Submissions Gateway (ESG) for the
receipt and processing of electronic
submissions provided so that the Center
for Biologics Evaluation and Research
(CBER), the Center for Drug Evaluation
and Research (CDER), and the Center for
Devices and Radiological Health (CDRH)
can receive regulatory submissions
electronically. The FDA ESG enables
applicants to send applications and
other submissions for review using the
Internet, provides a single point of entry
for these submissions, and fulfills goals
identified in the Prescription Drug User
Fee Act (PDUFA III).
E:\FR\FM\08AUN1.SGM
08AUN1
45058
Federal Register / Vol. 71, No. 152 / Tuesday, August 8, 2006 / Notices
FOR FURTHER INFORMATION CONTACT:
Michael B. Fauntleroy, CBER (HFM–25),
Food and Drug Administration, 11400
Rockville Pike, RKWL rm. 4119,
Rockville, MD 20857, 301–827–5132, email: michael.fauntleroy@fda.hhs.gov or
William H. Taylor, Office of the
Commissioner (HFA–83), Food and
Drug Administration, 5600 Fishers
Lane, rm. 16B–45, Rockville, MD 20857,
301–255–6734, e-mail:
william.taylor@fda.hhs.gov.
FDA
receives a variety of electronic
submissions under 21 CFR 11.2(b),
including biological license applications
(BLAs), new drug applications (NDAs),
drug master files (DMFs), investigational
new drug applications (INDs), and
investigational device exemptions
(IDEs), as well as their associated
correspondence and other types of
regulatory submissions. The FDA ESG
supports the receipt and processing of
electronic submissions through the use
of a single point of entry.
The increasing number of electronic
submissions highlights a critical need to
automate and standardize the receipt of
these submissions and their delivery to
the appropriate centers. The FDA ESG
automates the receipt, acknowledgment
(to the applicant/sponsor), routing, and
notification (to a receiving center) of
electronic submissions via the Internet
and meets the standards for the
electronic exchange of information
adopted by the American National
Standards Institute (ANSI) and the
National Institute of Standards and
Technology (NIST).
The FDA ESG offers two secure
communication options for applicants
that have established gateway systems.
One utilizes simple mail transfer
protocol (SMTP) with secure multipurpose internet mail extensions (S/
MIME) to provide secure e-mail
communication and the other supports
faster information exchange and utilizes
hypertext transfer protocol secure
(HTTPS) to provide real-time Internet
communication. The FDA ESG also
offers a secure WebTrader submission
option for applicants who do not have
gateway systems. The WebTrader is a
no-cost applet which can be
downloaded from FDA and requires
only a standard security certificate to
provide the applicants with a secure
Internet connection to FDA. The
WebTrader addresses the need to
expand participation in electronic
submissions without costly
expenditures for infrastructure upgrades
and gateway systems.
Use of the FDA ESG is voluntary.
Electronic format submissions may be
jlentini on PROD1PC65 with NOTICES
SUPPLEMENTARY INFORMATION:
VerDate Aug<31>2005
20:06 Aug 07, 2006
Jkt 208001
made through the gateway or may
continue to be made on physical media.
Information on the FDA ESG is available
on the following Web site: https://
www.fda.gov/esg/. Except where FDA
has promulgated regulations requiring
submission in electronic format,
applicants/sponsors may also continue
to make regulatory submissions on
paper.
If you wish to use the FDA ESG, you
should send an e-mail to
esgprep@fda.gov to begin the
registration process. Include your name,
phone number, and the name of the
company you represent. Please state
whether you are using the WebTrader,
SMTP, or HTTPS for submissions.
Dated: July 31, 2006.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. E6–12808 Filed 8–7–06; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. 2006D–0296]
International Conference on
Harmonisation; Draft Guidance on Q4B
Regulatory Acceptance of Analytical
Procedures and/or Acceptance
Criteria; Annex on Residue on Ignition/
Sulphated Ash General Chapter;
Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing the
availability of a draft guidance entitled
‘‘Q4B Regulatory Acceptance of
Analytical Procedures and/or
Acceptance Criteria; Annex 1: Residue
on Ignition/Sulphated Ash General.’’
The draft guidance was prepared under
the auspices of the International
Conference on Harmonisation of
Technical Requirements for Registration
of Pharmaceuticals for Human Use
(ICH). The draft guidance provides the
outcome of the ICH Q4B evaluation of
the Residue on Ignition/Sulphated Ash
General Chapter harmonized text from
each of the three pharmacopoeias
(United States, European, and Japanese)
represented by the Pharmacopoeial
Discussion Group (PDG). The draft
guidance conveys acceptance of the
three pharmacopoeial methods by the
three ICH regulatory regions and
provides specific information regarding
the acceptance. The draft guidance is
PO 00000
Frm 00065
Fmt 4703
Sfmt 4703
intended to recognize the
interchangeability between the local
regional pharmacopoeias, thus avoiding
redundant testing and different
acceptance criteria in favor of a common
testing strategy in each regulatory
region. Elsewhere in this issue of the
Federal Register, FDA is announcing the
availability of a draft guidance entitled
‘‘Q4B Regulatory Acceptance of
Analytical Procedures and/or
Acceptance Criteria.’’
Submit written or electronic
comments on the draft guidance by
October 10, 2006.
DATES:
Submit written requests for
single copies of the draft guidance to the
Division of Drug Information (HFD–
240), Center for Drug Evaluation and
Research, Food and Drug
Administration, 5600 Fishers Lane,
Rockville, MD 20857; or the Office of
Communication, Training and
Manufacturers Assistance (HFM–40),
Center for Biologics Evaluation and
Research (CBER), Food and Drug
Administration, 1401 Rockville Pike,
Rockville, MD 20852–1448. The
guidance may also be obtained by mail
by calling CBER at 1–800–835–4709 or
301–827–1800. Send two self-addressed
adhesive labels to assist the office in
processing your requests. Submit
written comments on the draft guidance
to the Division of Dockets Management
(HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852. Submit
electronic comments to https://
www.fda.gov/dockets/ecomments. See
the SUPPLEMENTARY INFORMATION section
for electronic access to the draft
guidance document.
ADDRESSES:
FOR FURTHER INFORMATION CONTACT:
Regarding the guidance: Robert H.
King, Sr., Center for Drug
Evaluation and Research (HFD–
003), Food and Drug
Administration, 10993 New
Hampshire Ave., Bldg. 21, rm. 3542,
Silver Spring, MD 20993–0002,
301–796–1242; or
Christopher Joneckis, Center for
Biologics Evaluation and Research
(HFM–20), Food and Drug
Administration, 1401 Rockville
Pike, Rockville, MD 20852, 301–
435–5681.
Regarding the ICH:Michelle Limoli,
Office of International Programs
(HFG–1), Food and Drug
Administration, 5600 Fishers
Lane,Rockville, MD 20857, 301–
827–4480.
SUPPLEMENTARY INFORMATION:
E:\FR\FM\08AUN1.SGM
08AUN1
Agencies
[Federal Register Volume 71, Number 152 (Tuesday, August 8, 2006)]
[Notices]
[Pages 45057-45058]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-12808]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. 1992S-0251] (formerly 92S-0251)
Food and Drug Administration Electronic Submissions Gateway
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing the
availability of the FDA Electronic Submissions Gateway (ESG) for the
receipt and processing of electronic submissions provided so that the
Center for Biologics Evaluation and Research (CBER), the Center for
Drug Evaluation and Research (CDER), and the Center for Devices and
Radiological Health (CDRH) can receive regulatory submissions
electronically. The FDA ESG enables applicants to send applications and
other submissions for review using the Internet, provides a single
point of entry for these submissions, and fulfills goals identified in
the Prescription Drug User Fee Act (PDUFA III).
[[Page 45058]]
FOR FURTHER INFORMATION CONTACT: Michael B. Fauntleroy, CBER (HFM-25),
Food and Drug Administration, 11400 Rockville Pike, RKWL rm. 4119,
Rockville, MD 20857, 301-827-5132, e-mail:
michael.fauntleroy@fda.hhs.gov or William H. Taylor, Office of the
Commissioner (HFA-83), Food and Drug Administration, 5600 Fishers Lane,
rm. 16B-45, Rockville, MD 20857, 301-255-6734, e-mail:
william.taylor@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: FDA receives a variety of electronic
submissions under 21 CFR 11.2(b), including biological license
applications (BLAs), new drug applications (NDAs), drug master files
(DMFs), investigational new drug applications (INDs), and
investigational device exemptions (IDEs), as well as their associated
correspondence and other types of regulatory submissions. The FDA ESG
supports the receipt and processing of electronic submissions through
the use of a single point of entry.
The increasing number of electronic submissions highlights a
critical need to automate and standardize the receipt of these
submissions and their delivery to the appropriate centers. The FDA ESG
automates the receipt, acknowledgment (to the applicant/sponsor),
routing, and notification (to a receiving center) of electronic
submissions via the Internet and meets the standards for the electronic
exchange of information adopted by the American National Standards
Institute (ANSI) and the National Institute of Standards and Technology
(NIST).
The FDA ESG offers two secure communication options for applicants
that have established gateway systems. One utilizes simple mail
transfer protocol (SMTP) with secure multi-purpose internet mail
extensions (S/MIME) to provide secure e-mail communication and the
other supports faster information exchange and utilizes hypertext
transfer protocol secure (HTTPS) to provide real-time Internet
communication. The FDA ESG also offers a secure WebTrader submission
option for applicants who do not have gateway systems. The WebTrader is
a no-cost applet which can be downloaded from FDA and requires only a
standard security certificate to provide the applicants with a secure
Internet connection to FDA. The WebTrader addresses the need to expand
participation in electronic submissions without costly expenditures for
infrastructure upgrades and gateway systems.
Use of the FDA ESG is voluntary. Electronic format submissions may
be made through the gateway or may continue to be made on physical
media. Information on the FDA ESG is available on the following Web
site: https://www.fda.gov/esg/. Except where FDA has promulgated
regulations requiring submission in electronic format, applicants/
sponsors may also continue to make regulatory submissions on paper.
If you wish to use the FDA ESG, you should send an e-mail to
esgprep@fda.gov to begin the registration process. Include your name,
phone number, and the name of the company you represent. Please state
whether you are using the WebTrader, SMTP, or HTTPS for submissions.
Dated: July 31, 2006.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. E6-12808 Filed 8-7-06; 8:45 am]
BILLING CODE 4160-01-S